A Phase 2, Seven Week, Double-Blind, Placebo Controlled, Randomized, Parallel Group Study To Evaluate The Safety And Efficacy Of Three Doses Of A Controlled Release Formulation Of Varenicline For Smoking Cessation

NCT00741884 Phase 2 WITHDRAWN

The purpose of this study is to evaluate the safety, efficacy, and tolerability of twice daily (BID) administration of three dose strengths (1.2 mg, 1.8 mg, and 2.4 mg) of varenicline controlled release (CR) tablets in adult smokers.

Details

Lead sponsor	Pfizer
Phase	Phase 2
Status	WITHDRAWN
Start date	2010-08
Completion	2011-08

Conditions

• Smoking Cessation

Interventions

• Varenicline Controlled Release 1.2 mg
• Varenicline Controlled Release 1.8 mg
• Varenicline Controlled Release 2.4 mg
• Varenicline Immediate Release 1 mg
• Placebo

Primary outcomes

• Continuous abstinence from smoking for weeks 4-7, carbon monoxide confirmed — 7 weeks